These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 30738364)

  • 1. Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
    Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G
    Cancer Treat Rev; 2019 Mar; 74():35-42. PubMed ID: 30738364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
    Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
    Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
    Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
    Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequencing of agents in castration-resistant prostate cancer.
    Lorente D; Mateo J; Perez-Lopez R; de Bono JS; Attard G
    Lancet Oncol; 2015 Jun; 16(6):e279-92. PubMed ID: 26065613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monitoring of treatment for metastatic castration-resistant prostate cancer].
    Hinz S
    Aktuelle Urol; 2017 May; 48(3):225-229. PubMed ID: 28614883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
    Lebdai S; Basset V; Branchereau J; de La Taille A; Flamand V; Lebret T; Murez T; Neuzillet Y; Ploussard G; Audenet F
    World J Urol; 2016 May; 34(5):617-24. PubMed ID: 26373956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
    Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H
    Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
    Parente P; Parnis F; Gurney H
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):205-15. PubMed ID: 24750803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
    Moussa M; Papatsoris A; Abou Chakra M; Sryropoulou D; Dellis A
    Expert Opin Pharmacother; 2020 Aug; 21(12):1431-1448. PubMed ID: 32469248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment options for patients with metastatic prostate cancer.
    Snoeks LL; Ogilvie AC; van Haarst EP; Siegert CE
    Neth J Med; 2013; 71(6):290-4. PubMed ID: 23956309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on treatment of metastatic castration-resistant prostate cancer.
    Merseburger AS; Bellmunt J; Jenkins C; Parker C; Fitzpatrick JM;
    Oncologist; 2013; 18(5):558-67. PubMed ID: 23671006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The third line of treatment for metastatic prostate cancer patients: Option or strategy?
    Roviello G; Petrioli R; Laera L; Francini E
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):265-71. PubMed ID: 26052050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of metastatic castration-resistant prostate cancer].
    Caffo O
    Recenti Prog Med; 2015 Jan; 106(1):35-9. PubMed ID: 25621779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment sequencing in metastatic castrate-resistant prostate cancer.
    Sartor O; Gillessen S
    Asian J Androl; 2014; 16(3):426-31. PubMed ID: 24675654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
    Bahl A
    Eur J Oncol Nurs; 2013 Sep; 17 Suppl 1():S1-6. PubMed ID: 24461207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic castration-resistant prostate cancer: time for innovation.
    Tucci M; Scagliotti GV; Vignani F
    Future Oncol; 2015; 11(1):91-106. PubMed ID: 25572785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.